US Biomax, Inc.

BL482

Bladder cancer tissue array, including TNM and pathology grade, 48 cases/48 cores

Microarray Panel:Bladder carcinoma tissue microarray, containing 48 cases of transitional cell carcinoma, single core per case
Cores:48
Cases:48
Layout:8 cols × 6 rows
Core Diameter:2 mm
Thickness:5 µm
Quality Control:Anti-Actin confirmed
Applications:Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes:Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.


Microarray Panel Display

 
Slide Label: US Biomax, Inc. Tissue Array
12345678 
A Bla Bla Bla Bla Bla Bla Bla Bla  
B Bla Bla Bla Bla Bla Bla Bla Bla  
C Bla Bla Bla Bla Bla Bla Bla Bla  
D Bla Bla Bla Bla Bla Bla Bla Bla  
E Bla Bla Bla Bla Bla Bla Bla Bla  
F Bla Bla Bla Bla Bla Bla Bla Bla Marked point
Legend: Bla - Bladder

- Malignant tumor, - Malignant tumor (stage II), - Malignant tumor (stage III)

Specification Sheet

Pos No. Sex Age Organ Pathology diagnosis Grade Stage TNM Type †
A1 1 M 61 Bladder Transitional cell carcinoma 1 II T2N0M0 Malignant
A2 2 F 56 Bladder Transitional cell carcinoma 1 II T2N0M0 Malignant
A3 3 M 52 Bladder Transitional cell carcinoma 1 II T2N0M0 Malignant
A4 4 M 72 Bladder Transitional cell carcinoma 1 II T2N0M0 Malignant
A5 5 F 25 Bladder Transitional cell carcinoma 1 II T2N0M0 Malignant
A6 6 M 53 Bladder Transitional cell carcinoma 1 II T2N0M0 Malignant
A7 7 F 79 Bladder Transitional cell carcinoma 1 II T2N0M0 Malignant
A8 8 M 56 Bladder Transitional cell carcinoma 1 II T2N0M0 Malignant
B1 9 M 66 Bladder Transitional cell carcinoma 1 II T2N0M0 Malignant
B2 10 M 69 Bladder Transitional cell carcinoma 1 II T2N0M0 Malignant
B3 11 M 48 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
B4 12 M 65 Bladder Transitional cell carcinoma (sparse) 2 II T2N0M0 Malignant
B5 13 M 70 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
B6 14 F 64 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
B7 15 M 42 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
B8 16 F 48 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
C1 17 M 70 Bladder Transitional cell carcinoma 1 II T2N0M0 Malignant
C2 18 M 70 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
C3 19 M 76 Bladder Transitional cell carcinoma 2 II T3aN0M0 Malignant
C4 20 M 72 Bladder Transitional cell carcinoma 2 II T3aN0M0 Malignant
C5 21 M 42 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
C6 22 M 69 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
C7 23 F 67 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
C8 24 M 70 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
D1 25 M 78 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
D2 26 M 71 Bladder Transitional cell carcinoma 2 II T2aN0M0 Malignant
D3 27 M 65 Bladder Transitional cell carcinoma 2 II T3aN0M0 Malignant
D4 28 F 50 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
D5 29 M 59 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
D6 30 M 45 Bladder Transitional cell carcinoma 2 III T3bN0M0 Malignant
D7 31 M 42 Bladder Transitional cell carcinoma 2 II T2aN0M0 Malignant
D8 32 F 70 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
E1 33 F 37 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
E2 34 M 44 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
E3 35 M 62 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
E4 36 M 60 Bladder Transitional cell carcinoma 3 II T3aN0M0 Malignant
E5 37 M 55 Bladder Transitional cell carcinoma 2 II T2N0M0 Malignant
E6 38 M 68 Bladder Transitional cell carcinoma 3 II T2aN0M0 Malignant
E7 39 M 61 Bladder Transitional cell carcinoma 3 II T2N0M0 Malignant
E8 40 M 64 Bladder Transitional cell carcinoma 3 II T2N0M0 Malignant
F1 41 M 52 Bladder Transitional cell carcinoma 3 II T2N0M0 Malignant
F2 42 F 61 Bladder Transitional cell carcinoma 3 II T3N0M0 Malignant
F3 43 F 65 Bladder Transitional cell carcinoma 3 II T3aN0M0 Malignant
F4 44 M 66 Bladder Transitional cell carcinoma 3 III T3N0M0 Malignant
F5 45 M 65 Bladder Transitional cell carcinoma 3 II T2N0M0 Malignant
F6 46 M 74 Bladder Transitional cell carcinoma 3 II T2N0M0 Malignant
F7 47 M 52 Bladder Transitional cell carcinoma 3 II T3N0M0 Malignant
F8 48 M 51 Bladder Transitional cell carcinoma 3 II T2N0M0 Malignant
M 58 Skin Malignant melanoma (tissue marker) Malignant

† For precise diagnosis, refer to pathology description.

**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.

TNM grading:

T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis

Find overlapping cases with this tissue array: